Showing 5441-5450 of 8207 results for "".
- Dr. Mary Lupo Joins Aquavit Pharmaceuticals' Scientific Advisory Boardhttps://practicaldermatology.com/news/20141106-dr_mary_lupo_joins_aquavit_pharmaceuticals_scientific_advisory_board/2459072/Mary Lupo, MD, FAAD has joined the US Scientific Advisory Board of Aquavit Pharmaceuticals. Dr. Lupo is a board-certified dermatologist who is internationally recognized for non-surgical skin rejuvenation. In 1984, she opened
- NYAM Academic Research Awards in Dermatology Program Accepting Applicationshttps://practicaldermatology.com/news/20141016-nyam_academic_research_awards_in_dermatology_program_accepting_applications/2459083/The application period is now open for the NYAM Academic Research Awards in dermatology program. Deadline for applications is December 15, 2014. The NYAM Academic Research Awards Program provides funding for residents and early-career dermatologists performing basic science or clinical research re
- Harvard Business Review Names Allergan's David E. I. Pyott a Top CEOhttps://practicaldermatology.com/news/20141015-harvard_business_review_names_allergans_david_e_i_pyott_a_top_ceo/2459084/David E.I. Pyott, Chairman of the Board and Chief Executive Officer of Allergan, Inc., has been ranked the 4th best-performing CEO in the world by the Harvard Business Review (HBR). Mr. Pyott was selected for this honor out of a total o
- INC Research Signs Agreement to Perform FDA Due Diligence Audit of Regulatory Documents for Provectus Biopharmaceuticalshttps://practicaldermatology.com/news/20141014-inc_research_signs_agreement_to_perform_fda_due_diligence_audit_of_regulatory_documents_for_provectus_biopharmaceuticals/2459085/Provectus Biopharmaceuticals, Inc. has retained INC Research, a leading, global Phase I to IV contract research organization, to conduct an FDA due diligence audit of its regulatory documents for PH-10 and PV-10. The audit will be conducted in two phases, both of which are expected to be
- Novartis data at EADV show consistent efficacy of AIN457 (secukinumab) in clearing skin of psoriasis patientshttps://practicaldermatology.com/news/20141013-novartis_data_at_eadv_show_consistent_efficacy_of_ain457_secukinumab_in_clearing_skin_of_psoriasis_patients/2459087/Novartis announced that new analyses of AIN457 (secukinumab) Phase III studies showed that treatment with secukinumab 300 mg resulted in higher rates of clear to almost clear skin at Week 12 versus placebo, regardless of patients' psoriasis disease severity (p<0.0001)[1].
- SKINPACT Program Launched with New Global Awards Initiative to Support the Dermatology Communityhttps://practicaldermatology.com/news/20141010-skinpact_program_launched_with_new_global_awards_initiative_to_support_the_dermatology_community/2459088/Galderma, in partnership with the International League of Dermatological Societies, has started a search for initiatives that will fulfill an important role in strengthening the global dermatology community. Galderma launched a new global initiative un
- AmSpa Welcomes Cathy Christensen as Executive Director or Operations and Communicationshttps://practicaldermatology.com/news/20141009-amspa_welcomes_cathy_christensen_as_executive_director_or_operations_and_communications/2459089/Cathy Christensen, former editor of Skin Inc. magazine and conference director for the Face and Body events, is now Executive Director or Operations and Communications of AmpSpa. Christensen said, "I have been honored to have a role in serving the professional skin care industry's profes
- Coronado Biosciences Forms Subsidiary to Acquire and License Dermatology Products for Commercializationhttps://practicaldermatology.com/news/20141008-coronado_biosciences_forms_subsidiary_to_acquire_and_license_dermatology_products_for_commercialization/2459090/Coronado Biosciences, Inc. has formed a wholly owned subsidiary called, Journey Medical Corporation (JMC) to acquire and license dermatology products. Under the leadership of Claude Maraoui, CEO, JMC will begin building a portfolio of dermatological assets focused on acne, steroid respons
- Peter Barton Hutt Appointed to Suneva Medical, Inc. Board Of Directorshttps://practicaldermatology.com/news/20141008-peter_barton_hutt_appointed_to_suneva_medical_inc_board_of_directors/2459093/Peter Barton Hutt was appointed a member of the Board of Directors of Suneva Medical, Inc., a privately-held aesthetics company. Mr. Hutt has specialized in food and drug law at the Washington, DC firm of Covington and Burling since 1960, pausing only to serve as Chief Counsel o
- Syneron Launches PicoWay Picosecond Device for Pigmented Lesion Treatment and Tattoo Removalhttps://practicaldermatology.com/news/20141008-syneron_launches_picoway_picosecond_device_for_pigmented_lesion_treatment_and_tattoo_removal/2459094/Syneron Medical Ltd. launched its new PicoWay picosecond device at the 23rd European Academy of Dermatology and Venereology (EADV) Congress, held in Amsterdam, The Netherlands, October 8-12, 2014. PicoWay is a dual wavelength device, with 532nm and 1064nm wavelengths, which util